TLR3 Agonist

OCALA, Fla., August 10, 2026 AIM ImmunoTech Inc. reported its second-quarter 2026 financial results and highlighted continued progress in...

OCALA, Fla., Aug. 3, 2026 AIM ImmunoTech Inc. announced that the final patient has received the last protocol-defined dose...

OCALA, Fla., June 24, 2026 AIM ImmunoTech Inc. highlighted significant progress across its pancreatic cancer development program, positioning Ampligen®...